SCHEMBL2320923

SCHEMBL2320923

Cc1nc2cccc(Cl)c2nc1-c1cccc(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.51
NR1H3 Q13133 1/20 0.51
PIK3CG P48736 6/20 0.45
PIK3CA P42336 3/20 0.45
MTOR P42345 2/20 0.45
PIK3CD O00329 1/20 0.45
PIK3C2B O00750 1/20 0.45
PDXK O00764 1/20 0.45
GAK O14976 1/20 0.45
MAP3K7 O43318 1/20 0.45
RIPK2 O43353 1/20 0.45
PIP5K1C O60331 1/20 0.45
STK16 O75716 1/20 0.45
PIK3C2G O75747 1/20 0.45
PRKD3 O94806 1/20 0.45
OXSR1 O95747 1/20 0.45
LATS1 O95835 1/20 0.45
ABL1 P00519 1/20 0.45
EGFR P00533 1/20 0.45
ERBB2 P04626 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4182457 0.83 NR1H2 (0.51) NR1H2NR1H3MGAMGAASI
SCHEMBL2320530 0.81 NR1H2 (0.53) NR1H2NR1H3PIK3CGPIK3CAMTOR
SCHEMBL2318698 0.75 NR1H2 (0.59) NR1H2NR1H3PIK3CGPIK3CAMTOR
SCHEMBL4180819 0.75 NQO2 (0.43) NR1H2NR1H3GAAPDE2APDE10A
SCHEMBL27895233 0.74 NR1H2 (0.48) NR1H2NR1H3MGAMGAASI
SCHEMBL8407324 0.73 MEN1 (0.51) NR1H2NR1H3PIK3CGFLT3GAA
SCHEMBL3492206 0.73 NR1H2 (0.91) NR1H2NR1H3DHODH
SCHEMBL2321967 0.72 HSD17B1 (0.56) PIK3CGPIK3CAPIK3CBHSD17B2TP53
SCHEMBL2322711 0.72 NR1H2 (0.66) NR1H2NR1H3
SCHEMBL10543210 0.72 PIK3CG (0.55) PIK3CGPIK3CAMTORPIK3CDPIK3C2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2352725-A1 QUINOXALINE-BASED LXR MODULATORS Wyeth LLC (US) 2011-08-10 EP disclosed
WO-2010054229-A1 QUINOXALINE-BASED LXR MODULATORS WYETH LLC (US) 2010-05-14 WO disclosed
US-20100120778-A1 QUINOXALINE-BASED LXR MODULATORS WYETH (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120778-A1 QUINOXALINE-BASED LXR MODULATORS NR1H2, NR1H3, NR1H4 NR1H2 1/4885NR1H3 2/4885PIK3CG 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.